Jul 30 2015
Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for ibrutinib (Imbruvica®), a promising oral therapy, for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL).
Jul 21 2015
A recent study shows that patients with a specific molecular subtype of diffuse large B-cell lymphoma (DLBCL) are more likely to respond to ibrutinib (Imbruvica) than patients with another molecular subtype of the disease.
Jul 20 2015
A new study finds evidence that a genetic enzyme deficiency that affects the ability of cells to produce energy may be behind an often-fatal blood cancer called diffuse large B-cell lymphoma (DLBCL).
Jun 17 2015
Mainway Social Committee, comprised of Metroland Media employees in Burlington, work together to organize a Bake Sale and 50/50 Draw to raise funds for Lymphoma Canada.
Jun 14 2015
The 2015 Congress provided a forum for presenting original unpublished data and sharing ideas for hematological innovation as well as disseminating evidence-based knowledge of primary clinical relevance.
Jun 12 2015
On June 12, 2015, Hungry Brew Hops hosted a tap-takeover event where they presented Lymphoma Canada with a $2,000 cheque from their fundraising initiatives.
Jun 03 2015
In response to yesterday's publication of the new reimbursable drugs list, the Coalition Priorité Cancer au Québec is asking the Minister of Health and Social Services to speed up revision of the new drugs evaluation and listing process.
Jun 02 2015
People in Quebec living with Chronic Lymphocytic Leukemia (CLL) will now be able to access a new treatment option through the province's prescription drug insurance plan.
Jun 01 2015
Burkitt’s lymphoma (BL) is a type of non-Hodgkin lymphoma. It is characterized by a mutation in a gene called myc, which triggers the BL cells to grow uncontrollably. However, much is still unknown about the cause of the disease.